The differential contributions of the CTLA-4 and PD-1 co-inhibitory receptors create diverse expression phenotypes, which may explain the varied efficacy of ICIs across tumor types, as well as their distinct toxicity profiles. Here, PDCD1 is linked to neoplasm.